Company / Cash & Equivalents
Cogent Biosciences, Inc. Cash & Equivalents History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$312.0M
FY2025
5-year range
$53.2M / $312.0M
FY2021-FY2025
Trend
+217.8%
vs FY2024
Sector context
#64 of 209
Health Care
What the data says
Cash & Equivalents changed +218% YoY in FY2025, a notable deviation from the 8-year average annual change of +101%.
Based on SEC 10-K filings.
$312M in FY2025 with a 5-year CAGR of +5.2%.
Improved from $53M to $312M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +30.7%
- 5-Year CAGR
- +5.2%
- 10-Year CAGR
- -
Sector benchmark
#64 of 209 in Health CareTop 31% of 209This company $312.0M Sector average $696.0M
▼
-55.2% below sector average
Key checks
Key Insights
- 5-year CAGR of +5.2%, indicating consistent growth.
- In FY2025, cash & equivalents increased 217.8% year-over-year.
- Ranks #64 out of 209 companies in the Health Care sector.
- Lowest cash & equivalents in the period was in FY2017.
Company context
Key Data Points
- Altman Z-Score 0.43 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $312.0M | +217.8% |
| FY2024 | $98.2M | +84.4% |
| FY2023 | $53.2M | -61.9% |
| FY2022 | $139.9M | -36.3% |
| FY2021 | $219.7M | -9.3% |
| FY2020 | $242.2M | +547.2% |
| FY2019 | $37.4M | -32.8% |
| FY2018 | $55.7M | +96.9% |
| FY2017 | $28.3M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026